Form 4: Neogenomics Executive Reports Stock Transactions
Statement of Changes in Beneficial Ownership
Warren Stone, President & COO of Neogenomics Inc., reported transactions involving stock options, restricted stock units, and performance stock units on May 2, 2026.
Summary
- Warren Stone, President & Chief Operating Officer of Neogenomics Inc. (NEO), filed a Form 4 detailing several transactions related to his beneficial ownership of company securities.
- These transactions include the release of restricted stock units (RSUs) and the acquisition of common stock, as well as various grants of stock options, RSUs, and performance stock units (PSUs).
- A disposition of shares occurred to satisfy tax withholding obligations related to the release of RSUs.
- The filing also details the grant dates, exercise prices, vesting schedules, and underlying securities for multiple stock options, RSUs, and PSUs awarded to Mr. Stone.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine executive equity transactions and compensation, without providing new financial performance data or strategic shifts.
Positives
- The filing indicates ongoing equity awards to a key executive, suggesting continued incentive alignment with company performance.
- The disposition of shares for tax withholding is a standard and expected event upon the vesting of RSUs.
Negatives
- The filing does not contain information that would be considered negative in isolation, as it primarily reports on executive compensation and equity grants.
Risks
- The vesting schedules and performance criteria for PSUs are subject to future company performance, including stock price and revenue growth, which introduces inherent risk.
- The exercise prices of stock options represent a potential cost to the executive, and their value is tied to the future stock price of NeoGenomics.
Future Outlook
The filing details various equity awards with future vesting dates and performance conditions, indicating a forward-looking compensation strategy tied to continued service and company performance metrics such as stock price and revenue growth.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard for executives and directors in the biotechnology and life sciences sector, reflecting common compensation practices involving equity incentives to align management interests with shareholder value.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President & Chief Operating Officer | Warren Stone | 04/01/2025 | Promotion |
Stakeholder Impact
- Shareholders: The ongoing equity awards to management are intended to align executive interests with shareholder value creation.
- Employees: The filing pertains to executive compensation and does not directly detail broader employee impacts.
- Management: The filing details compensation packages for a key executive, reflecting incentives and ownership stakes.
Next Steps
- Vesting of granted stock options, restricted stock units, and performance stock units according to their respective schedules.
- Potential exercise of vested stock options.
- Achievement of performance criteria for performance stock units.
Key Dates
| Date | Description |
|---|---|
| 01/13/2026 | Grant date for a Restricted Stock Unit award. |
| 02/23/2024 | Grant date for Stock Options, Performance Stock Units, and Restricted Stock Units. |
| 02/21/2025 | Grant date for Stock Options and Restricted Stock Units, with subsequent vesting schedule modification. |
| 03/01/2026 | Grant date for Stock Options and Restricted Stock Units. |
| 04/01/2025 | Effective date of promotion to President & Chief Operating Officer, leading to vesting schedule modifications for certain equity awards. Grant date for Stock Options and Restricted Stock Units. |
| 05/02/2026 | Earliest transaction date reported in the filing. Transaction date for release of RSUs and acquisition of common stock, and grant date for Stock Options and Performance Stock Units. |
| 05/11/2023 | Grant date for Stock Options, Performance Stock Units, and Restricted Stock Units. |
| 12/01/2022 | Grant date for Stock Options. |
Keywords
Form 4, SEC Filing, Neogenomics, NEO, Warren Stone, Stock Options, Restricted Stock Units, Performance Stock Units, Beneficial Ownership, Executive Compensation, Equity Awards
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.